Open-label, Multicentre Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Ceftaroline In Neonates And Young Infants With Late-onset Sepsis
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Ceftaroline fosamil (Primary)
- Indications Sepsis
- Focus Adverse reactions
- Sponsors AstraZeneca; Pfizer
- 23 Mar 2018 Status changed from recruiting to completed.
- 10 Oct 2017 Planned End Date changed from 9 Oct 2017 to 18 Sep 2021.
- 10 Oct 2017 Planned primary completion date changed from 9 Oct 2017 to 18 Sep 2021.